Managing the underlying cause of cystic fibrosis: A future role for potentiators and correctors

Pediatric Drugs

Volumn 15, Issue 5, 2013, Pages 393-402

  Galietta, Luis J V ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885670457     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0035-3     Document Type: Review

References (84)

1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-65.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-73.
3. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-80.
4. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem. 2008;77:701-26.
5. Kim SJ, Skach WR. Mechanisms of CFTR folding at the endoplasmic reticulum. Front Pharmacol. 2012;3:201.
6. Poulsen JH, Fischer H, Illek B, et al. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA. 1994;91(12):5340-4.
7. Tabcharani JA, Linsdell P, Hanrahan JW. Halide permeation in wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels. J Gen Physiol. 1997;110(4):341-54.
8. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005-15.
9. Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest. 2007;132(5):1631-6.
10. Garcia-Caballero A, Rasmussen JE, Gaillard E, et al. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci USA. 2009;106(27):11412-7.
11. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119(9):2613-22.
12. Gustafsson JK, Ermund A, Ambort D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med. 2012;209(7):1263-72.
13. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487(7405):109-13.
14. Simmonds NJ, Macneill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J. 2010;36(6):1277-83.
15. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros. 2008;7(6):537-42.
16. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011;28(342):d1008.
17. Atkinson TJ. Cystic fibrosis, vector-mediated gene therapy, and relevance of toll-like receptors: a review of problems, progress, and possibilities. Curr Gene Ther. 2008;8(3):201-7.
18. Oakland M, Sinn PL, McCray PB Jr. Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther. 2012;20(6):1108-15.
19. Illek B, Zhang L, Lewis NC, et al. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol. 1999;277(4 Pt 1):C833-9.
20. Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 1992;358(6389):761-4.
21. Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci USA. 2008;105(9):3256-61.
22. Vergani P, Lockless SW, Nairn AC, et al. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature. 2005;433(7028):876-80.
23. - channel by ATP-driven nucleotide-binding domain dimerisation. J Physiol. 2009;587(Pt 10):2151-61.
24. Younger JM, Chen L, Ren HY, et al. Sequential quality-control checkpoints triage misfolded cystic fibrosis transmembrane conductance regulator. Cell. 2006;126(3):571-82.
25. Farinha CM, Amaral MD. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol. 2005;25(12):5242-52.
26. Penque D, Mendes F, Beck S, et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest. 2000;80(6):857-68.
27. Okiyoneda T, Barrière H, Bagdány M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010;329(5993):805-10.
28. Lukacs GL, Chang XB, Bear C, et al. The deltaF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem. 1993;268(29):21592-8.
29. Sharma M, Pampinella F, Nemes C, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol. 2004;164(6):923-33.
30. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the deltaF508 cystic fibrosis mutation. Nature. 1991;354(6354):526-8.
31. Drumm ML, Wilkinson DJ, Smit LS, et al. Chloride conductance expressed by deltaF508 and other mutant CFTRs in Xenopus oocytes. Science. 1991;254(5039):1797-9.
32. Haws CM, Nepomuceno IB, Krouse ME, et al. DeltaF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol. 1996;270(5 Pt 1):C1544-55.
33. Wang F, Zeltwanger S, Hu S, et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol. 2000;1(524 Pt 3):637-48.
34. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251-4.
35. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995;29:777-807.
36. Haardt M, Benharouga M, Lechardeur D, et al. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem. 1999;274(31):21873-7.
37. Hwang TC, Wang F, Yang IC, et al. Genistein potentiates wild-type and deltaF508-CFTR channel activity. Am J Physiol. 1997;273(3 Pt 1):C988-98.
38. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009;8(2):153-71.
39. Zegarra-Moran O, Romio L, Folli C, et al. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol. 2002;137(4):504-12.
40. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol. 2005;67(5):1797-807.
41. Dérand R, Bulteau-Pignoux L, Mettey Y, et al. Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Am J Physiol. 2001;281(5):C1657-66.
42. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem. 2003;278(37):35079-85.
43. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol. 2005;68(6):1736-46.
44. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564-71.
45. Norez C, Noel S, Wilke M, et al. Rescue of functional deltaF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 2006;580(8):2081-6.
46. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem. 2007;8(9):1012-20.
47. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825-30.
48. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol. 2010;6(1):25-33.
49. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108(46):18843-8.
50. Carlile GW, Keyzers RA, Teske KA, et al. Correction of F508del-CFTR trafficking by the sponge alkaloid latonduine is modulated by interaction with PARP. Chem Biol. 2012;19(10):1288-99.
51. Caputo A, Hinzpeter A, Caci E, et al. Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators. J Pharmacol Exp Ther. 2009;330(3):783-91.
52. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237-45.
53. Pedemonte N, Tomati V, Sondo E, et al. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol. 2010;298(4):C866-74.
54. Randell SH, Fulcher ML, O'Neal W, et al. Primary epithelial cell models for cystic fibrosis research. Methods Mol Biol. 2011;742:285-310.
55. Fulcher ML, Randell SH. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol Biol. 2013;945:109-21.
56. Mendoza JL, Schmidt A, Li Q, et al. Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences. Cell. 2012;148(1-2):164-74.
57. Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell. 2012;148(1-2):150-63.
58. Roxo-Rosa M, Xu Z, Schmidt A, et al. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci USA. 2006;103(47):17891-6.
59. DeCarvalho AC, Gansheroff LJ, Teem JL. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator â̂† F508. J Biol Chem. 2002;277(39):35896-905.
60. Thibodeau PH, Richardson JM 3rd, Wang W, et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem. 2010;285(46):35825-35.
61. Grove DE, Rosser MF, Ren HY, et al. Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol Biol Cell. 2009;20(18):4059-69.
62. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003.
63. De Boeck K, Derichs N, Fajac I, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros. 2011;10(Suppl 2):S53-66.
64. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-72.
65. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718-24.
66. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12-8.
67. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349(15):1433-41.
68. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87-91.
69. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;182(10):1262-72.
70. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38(1):59-69.
71. Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest. 2007;117(3):683-92.
72. Rowe SM, Sloane P, Tang LP, et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl). 2011;89(11):1149-61.
73. Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther. 2004;311(3):929-38.
74. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther. 2008;325(1):77-88.
75. Rowe SM, Reeves G, Hathorne H, et al. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in cystic fibrosis subjects. Chest. 2013;. doi: 10.1378/chest.12-2431.
76. Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):539-49.
77. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013;162(4):676-80.
78. Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210-5.
79. Schroeder BC, Cheng T, Jan YN, et al. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell. 2008;134(6):1019-29.
80. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322(5901):590-4.
81. Scudieri P, Caci E, Bruno S, et al. Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol. 2012;590(Pt 23):6141-55.
82. Namkung W, Phuan PW, Verkman AS. TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-activated chloride channel conductance in airway and intestinal epithelial cells. J Biol Chem. 2011;286(3):2365-74.
83. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of Ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013 (Epub ahead of print).
84. Boyle MP, Bell S, Konstan M, et al. The investigational CFTR corrector, VX-809 (Lumacaftor) co-administered with the oral potentiator Ivacaftor improved CFTR and lung function in F508del homozygous patients: phase II study results. Pediatr Pulmonol. 2012;47(S35):315.